Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Domvanalimab (DOM)
Domvanalimab · 2 trials · 2 indications
ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using investigator assessments.
PFS is defined as the time from the date of randomization until the first date of documented progressive disease (PD) or death from any cause, whichever occurs first, as measured by RECIST v1.1 using investigator assessments.
| Arm | Type | Description |
|---|---|---|
| Treatment Group A: Domvanalimab (DOM) + Zimberelimab (ZIM) + Platinum-based Chemotherapy | EXPERIMENTAL | Participants will receive DOM + ZIM + platinum-based chemotherapy (paclitaxel + carboplatin). |
| Treatment Group B: Zimberelimab (ZIM) + Platinum-based Chemotherapy | EXPERIMENTAL | Participants will receive ZIM + platinum-based chemotherapy (paclitaxel + carboplatin). |
| A1: Domvanalimab + Zimberelimab | EXPERIMENTAL | Domvanalimab and Zimberelimab, both administered by IV infusion |
| A2: Domvanalimab + Zimberelimab | EXPERIMENTAL | Domvanalimab and Zimberelimab, both administered by IV infusion |
| A3: Quemliclustat + Zimberelimab | EXPERIMENTAL | Quemliclustat and Zimberelimab, both administered by IV infusion |
| B1: Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Quemliclustat, zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| B2: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| B3: Domvanalimab + Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Domvanalimab, Quemliclustat, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| B4: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| B5: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy | EXPERIMENTAL | Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion |
| C1: Quemliclustat + Zimberelimab + Docetaxel | EXPERIMENTAL | Quemliclustat, Zimberelimab, and Docetaxel, all administered by IV infusion |
| C2: Domvanalimab + Zimberelimab + Docetaxel | EXPERIMENTAL | Domvanalimab, Zimberelimab, and Docetaxel, all administered by IV infusion |
| Name | Type | Description |
|---|---|---|
| Domvanalimab | DRUG | Administered intravenously |
| Zimberelimab | DRUG | Administered intravenously |
| Paclitaxel | DRUG | Administered intravenously |
| Carboplatin | DRUG | Administered intravenously |
| Quemliclustat | DRUG | Administered as specified in the treatment arm |
| Docetaxel | DRUG | Administered as specified in the treatment arm |
| Platinum-Based Doublet | DRUG | Administered as specified in the treatment arm |
Key Inclusion Criteria: * Histologically or cytologically confirmed r/m squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies. * No prior systemic therapy for r/m HNSCC. Individuals who had disease progression or recurrence m...
Top 20 of 83 competitors
Domvanalimab is an investigational small molecule being studied for the treatment of Head and Neck Squamous Cell Carcinoma and Advanced Non-Small Cell Lung Cancer. It is currently in Phase 2 clinical development and has not been approved by the FDA.
Domvanalimab targets TIGIT, an inhibitory receptor, and acts as a TIGIT inhibitor. By blocking TIGIT, it is designed to enhance the immune system's ability to fight cancer cells. This mechanism is being evaluated in ongoing clinical trials for solid tumors.
Domvanalimab is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical trials to evaluate the drug's safety and efficacy in oncology indications.
Domvanalimab is currently in Phase 2 clinical trials. It is an investigational drug, meaning it has not yet received regulatory approval. The ongoing studies are assessing its use in Advanced Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma.
Domvanalimab is being studied in two active Phase 2 trials. NCT05676931 enrolls 400 participants with Advanced Non-Small Cell Lung Cancer across multiple countries. NCT06727565 enrolls 39 participants with Head and Neck Squamous Cell Carcinoma. Both trials are active but not recruiting.
Yes, Domvanalimab is also known as DOM. This abbreviation is used in clinical and research contexts to refer to the same investigational drug. Both names refer to the TIGIT inhibitor being developed by Gilead Sciences.